Loading
journalsJournal
Cancers
A high-volume open-access oncology journal from MDPI publishing thousands of papers a year across basic, translational and clinical cancer research.
Also called: Cancers (Basel)
Overview
Fully open access with article processing charges and rapid turnaround, publishing thousands of original articles and reviews a year, often in special issues. Widely indexed and read, though MDPI's volume and speed have drawn scrutiny; treat individual findings with the usual care and check for replication.
Publisher
MDPI
Scope
clinical oncology
Website
Access model
open access
Founded
2009
ISSN
2072-6694
review20262 citations
FGFR2-Rearranged Biliary Tract Cancer: Biology, Resistance Mechanisms, and Emerging Therapeutic Strategies
One of the most cited reviews Europe PMC returns for FGFR2 in Biliary tract cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
review20255 citations
Expression and Clinical Significance of CD47 in Colorectal Cancer: A Review
One of the most cited reviews Europe PMC returns for CD47 in Colorectal cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
methods2022151 citations
NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test
NHS-Galleri is the trial that will decide whether a blood test for many cancers at once should be offered by a health system. Its endpoint is a reduction in late-stage cancer rather than deaths, so even a positive result leaves the mortality question to be settled by longer follow-up.
observational202125 citations
Programmed death ligand-1 (PD-L1) is an independent negative prognosticator in Western-world gallbladder cancer
The Western counterpart to the Indian series, with lower rates and a prognostic signal in the opposite direction from what immunotherapy enthusiasts might hope. The TIGIT and CD155 finding names a second checkpoint for future trials.
observational202145 citations
Validation of the 8th Edition American Joint Commission on Cancer (AJCC) Gallbladder Cancer Staging System: Prognostic Discrimination and Identification of Key Predictive Factors
Anatomy alone explains only about two thirds of the ranking of who lives longer; the 2026 staging review makes the same point and argues for molecular and nodal-burden modifiers alongside TNM.
review2019116 citations
Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma
One of the most cited reviews Europe PMC returns for Tebentafusp in Melanoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Alinta Hegmane
Representative of Riga East University Hospital / Oncology Centre of Latvia to the Organisation of European Cancer Institutes
Cancer centre representation (OECI)
Alinta Hegmane represents Riga East University Hospital / Oncology Centre of Latvia in the Organisation of European Cancer Institutes, which lists the centre among its members in Latvia.
Christian Brandts
Director, UCT Frankfurt (Geschäftsführender Direktor)
Haematology and medical oncologyLeukaemiaCancer centre management
Haematologist-oncologist who is Managing Director of the University Cancer Center Frankfurt.
Diane M. Simeone
Director, Moores Cancer Center; Koman Family Presidential Director's Chair
Pancreatic cancerSurgical oncologyCancer early detection
Pancreatic cancer surgeon-scientist who directs UC San Diego Moores Cancer Center, an NCI-designated comprehensive cancer center.
Giampaolo Tortora
Director, Comprehensive Cancer Center, Gemelli; Professor of Medical Oncology
Medical oncologyPancreatic cancerTargeted therapy
Giampaolo Tortora is a medical oncologist who directs the Gemelli comprehensive cancer centre.
Hitoshi Ishikawa
Director of QST Hospital
Radiation oncologyCarbon ion radiotherapyHeavy ion therapy
Radiation specialist who has directed QST Hospital in Chiba, Japan's pioneering carbon ion radiotherapy hospital, since April 2024.
Ivan S. Stilidi
Representative of N. N. Blokhin National Medical Research Center of Oncology to the Organisation of European Cancer Institutes
Cancer centre representation (OECI)
Ivan S. Stilidi represents N. N. Blokhin National Medical Research Center of Oncology in the Organisation of European Cancer Institutes, which lists the centre among its associate members in the Russian Federation.
Peter Sasieni
Professor of Cancer Epidemiology, Queen Mary University of London; Director, Cancer Prevention Trials Unit
Cervical screeningHPV vaccination evaluationScreening trial design
Epidemiologist who showed HPV vaccination has nearly eliminated cervical cancer in vaccinated English women and leads NHS-Galleri.
Polina Stepensky
Director, Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center
Haematopoietic stem cell transplantationAcademic CAR-T manufactureMultiple myeloma
Runs a hospital department that makes its own CAR-T cells and gives them fresh, without freezing, at a fraction of what a commercial product costs.
Rachel Michaelson-Cohen
Gynaecologist and medical geneticist, Shaare Zedek Medical Center; chair of the Israeli Consortium harmonising national BRCA carrier care
Hereditary breast and ovarian cancerRisk-reducing surgeryHealth policy
Led the work of turning nine Israeli high-risk clinics, which were each doing something different, into one national protocol for looking after the carriers the screening programme keeps finding.
Ruben Mesa
Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, and President of the Cancer Service Line
Haematology and oncologyCancer centre leadershipAcademic medicine
Physician who is Executive Director of the NCI-designated Atrium Health Wake Forest Baptist Comprehensive Cancer Center in Winston-Salem and President of its cancer service line.
Shivaani Kummar
Chief Scientific and Academic Officer, Knight Cancer Group and Director, Knight Cancer Institute
Early-phase drug developmentMedical oncologyPrecision oncology
Drug development oncologist who directs the OHSU Knight Cancer Institute.
Tatsuya Ohno
Director of the Gunma University Heavy Ion Medical Center
Carbon-ion radiotherapyRadiation oncologyParticle therapy
Carbon-ion radiotherapy specialist who directs the Gunma University Heavy Ion Medical Center, Japan's first university-based carbon-ion cancer treatment facility.
Vincent K. Tuohy
Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research, Lerner Research Institute
Preventive cancer vaccinesAlpha-lactalbuminTriple-negative breast cancer
Vincent Tuohy invented a preventive vaccine against triple-negative breast cancer, now in early human trials.
reviewCancers 20262 citations
FGFR2-Rearranged Biliary Tract Cancer: Biology, Resistance Mechanisms, and Emerging Therapeutic Strategies
One of the most cited reviews Europe PMC returns for FGFR2 in Biliary tract cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
reviewCancers 20255 citations
Expression and Clinical Significance of CD47 in Colorectal Cancer: A Review
One of the most cited reviews Europe PMC returns for CD47 in Colorectal cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
methodsCancers 2022151 citations
NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test
NHS-Galleri is the trial that will decide whether a blood test for many cancers at once should be offered by a health system. Its endpoint is a reduction in late-stage cancer rather than deaths, so even a positive result leaves the mortality question to be settled by longer follow-up.
observationalCancers 202125 citations
Programmed death ligand-1 (PD-L1) is an independent negative prognosticator in Western-world gallbladder cancer
The Western counterpart to the Indian series, with lower rates and a prognostic signal in the opposite direction from what immunotherapy enthusiasts might hope. The TIGIT and CD155 finding names a second checkpoint for future trials.
reviewCancers 2019116 citations
Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma
One of the most cited reviews Europe PMC returns for Tebentafusp in Melanoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Similar pages
- JournalCancer medicine
Shares Ruben Mesa, PubMed & Europe PMC.
collections
people
key papers
Expression and Clinical Significance of CD47 in Colorectal Cancer: A ReviewFGFR2-Rearranged Biliary Tract Cancer: Biology, Resistance Mechanisms, and Emerging Therapeutic StrategiesNHS-Galleri: design of the largest randomised trial of a multi-cancer blood testProgrammed death ligand-1 (PD-L1) is an independent negative prognosticator in Western-world gallbladder cancerTebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma